Recombinant Rat TPP1 Protein Pre-coupled Magnetic Beads

• Cat.No.: TPP1-5902R-B
• Product Overview: The Recombnant protein was conjugated to magnetic beads. This ready-to-use, pre-coupled magnetic beads are in uniform particle size and narrow size distribution with large surface area, which is conducive to convenient and fast capture target molecules with high specificity and achieve magnetic separation. This product can be equipped with automation equipment for high-throughput operations.

Specification

• Source: HEK293
• Species: Rat
• Form: Solution
• Particle size: ~2 μm
• Beads Surface: Hydrophilic
• Capacity: > 200 pmol rabbit IgG/ mg beads
• Applications: Immunoassay, In vitro diagnostics, cell sorting, Immunoprecipitation/Co-precipitation, Protein/antibody separation and purification.
• Stability: Stable for at least 6 months from the date of receipt of the product under proper storage and handling conditions.
• Storage: 2-8℃. Do not to freeze thaw the Beads
• Concentration: 10mg beads/mL
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: Tpp1 tripeptidyl peptidase I [ Rattus norvegicus ]
• Official Symbol: TPP1
• Gene ID: 83534
• mRNA Refseq: NM_031357.1
• Protein Refseq: NP_112647.1
• UniProt ID: Q9EQV6

Reviews

06/23/2019

These resources can enhance the efficiency and accuracy of experimental workflows and contribute to successful outcomes.

12/07/2018

The manufacturer's support is crucial for researchers using TPP1 protein in trials.

09/16/2018

Their collaboration, expertise, and customized solutions contribute to the successful execution of experiments, reliable data generation, and the advancement of scientific knowledge in the field.

Q&As

Are there any specific inhibitors developed to target PKMYT1?

Yes, several PKMYT1 inhibitors are under development and in preclinical and clinical trials for evaluating their efficacy in cancer treatment.

Are there ongoing clinical trials targeting PKMYT1?

Yes, several clinical trials are investigating the efficacy of PKMYT1 inhibitors in various cancer types.

How does PKMYT1 influence cell cycle progression?

PKMYT1 regulates the cell cycle by inhibiting the activity of cyclin-dependent kinases (CDKs), particularly CDK1, which is crucial for G2/M phase transition.

Can PKMYT1 be used as a predictive biomarker in cancer patients?

Yes, the expression levels of PKMYT1 can be indicative of the responsiveness of cancer cells to specific treatments, making it a potential predictive biomarker.

How does PKMYT1 inhibition affect normal cell function?

Selective PKMYT1 inhibitors aim to minimize effects on normal cells, but potential impacts on the cell cycle of non-cancerous cells are still under investigation.